Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. (2014)
Attributed to:
Second Generation Sustainable Bacterial Biofuels
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.1761
PubMed Identifier: 24732092
Publication URI: http://europepmc.org/abstract/MED/24732092
Type: Journal Article/Review
Volume: 5
Parent Publication: Oncotarget
Issue: 7
ISSN: 1949-2553